Glycyrrhizic acid promotes sciatic nerves recovery in type 1 diabetic rats and protects Schwann cells from high glucose-induced cytotoxicity

Min Shi; Xiangcheng Zhang; Ridong Zhang; Hong Zhang; Dalong Zhu; Xiao Han

doi:10.7555/JBR.36.20210198

Volume 36 Issue 3

May 2022

Turn off MathJax

Article Contents

Article Navigation > The Journal of Biomedical Research > 2022 > 36(3): 181-194

Min Shi, Xiangcheng Zhang, Ridong Zhang, Hong Zhang, Dalong Zhu, Xiao Han. Glycyrrhizic acid promotes sciatic nerves recovery in type 1 diabetic rats and protects Schwann cells from high glucose-induced cytotoxicity[J]. The Journal of Biomedical Research, 2022, 36(3): 181-194. doi: 10.7555/JBR.36.20210198

Citation:

Min Shi, Xiangcheng Zhang, Ridong Zhang, Hong Zhang, Dalong Zhu, Xiao Han. Glycyrrhizic acid promotes sciatic nerves recovery in type 1 diabetic rats and protects Schwann cells from high glucose-induced cytotoxicity[J]. The Journal of Biomedical Research, 2022, 36(3): 181-194. doi: 10.7555/JBR.36.20210198

Citation:

Min Shi, Xiangcheng Zhang, Ridong Zhang, Hong Zhang, Dalong Zhu, Xiao Han. Glycyrrhizic acid promotes sciatic nerves recovery in type 1 diabetic rats and protects Schwann cells from high glucose-induced cytotoxicity[J]. The Journal of Biomedical Research, 2022, 36(3): 181-194. doi: 10.7555/JBR.36.20210198

PDF( 4256 KB)

Glycyrrhizic acid promotes sciatic nerves recovery in type 1 diabetic rats and protects Schwann cells from high glucose-induced cytotoxicity

doi: 10.7555/JBR.36.20210198

Min Shi^{1, 2, 3},
Xiangcheng Zhang⁴,
Ridong Zhang³,
Hong Zhang^{3
,
,},
Dalong Zhu^{2
,
,},
Xiao Han^{1
,
,}

1.
Key Laboratory of Human Functional Genomics of Jiangsu Province, Department of Biochemistry and Molecular Biology, Nanjing Medical University, Nanjing, Jiangsu 211166, China
2.
Department of Endocrinology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu 210008, China
3.
Department of Endocrinology, the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, China
4.
Department of Intensive Care Unit, the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, Huai'an, Jiangsu 223300, China

More Information

Corresponding author: Hong Zhang, Department of Endocrinology, the Affiliated Huai'an No. 1 People's Hospital of Nanjing Medical University, 6 West Beijing Road, Huai'an, Jiangsu 223300, China. Tel: +86-517-80872128, E-mail: zhh79318@163.com; Dalong Zhu, Department of Endocrinology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, 321 Zhongshan Road, Nanjing, Jiangsu 210008, China. Tel: +86-25-83304616, E-mail: zhudldr@gmail.com; Xiao Han, Key Laboratory of Human Functional Genomics of Jiangsu Province, Department of Biochemistry and Molecular Biology, Nanjing Medical University, 101 Longmian Avenue, Nanjing, Jiangsu 211166, China. Tel: +86-25-86869426, E-mail: hanxiao@njmu.edu.cn
Received: 2021-11-24
Revised: 2022-03-08
Accepted: 2022-03-16

Published: 2022-05-15

Issue Date: 2022-05-28

Abstract

Abstract

The present study aims to investigate the therapeutic effect and mechanism of glycyrrhizic acid (GA) in diabetic peripheral neuropathy (DPN). GA significantly mitigated nerve conduction velocity (NCV) deficit and morphological abnormality and reduced high-mobility group box-1 (HMGB1) expression in the sciatic nerves of diabetic rats independent of blood glucose and body weight. Notably, GA alleviated the increase of HMGB1 and the decrease of cell viability in high glucose-stimulated RSC96 cells. Furthermore, GA obviously reduced the concentration of inflammatory cytokines in the sciatic nerves of diabetic rats and supernatants of high glucose-exposed RSC96 cells, then restored the decreased expression levels of nerve growth factor (NGF) and neuritin-1, and the increased expression levels of cleaved caspase-3 and neuron-specific enolase. Additionally, GA markedly inhibited receptor for advanced glycation end products (RAGE) expression, p38MAPK phosphorylation, and the nuclear translocation of NF-κBp65 in diabetic rats and high glucose-exposed RSC96 cells. The promotional effect of high glucose in RSC96 cells was diminished following Hmgb1 siRNA treatment. Our findings indicate that GA may exert neuroprotection on DPN by suppressing HMGB1, which lead to extenuation of inflammation response, balance of NGF, neuritin-1 and caspase-3, as well as inactivation of RAGE/p38MAPK/NF-κBp65 signaling pathway.
- diabetic peripheral neuropathy,
- glycyrrhizic acid,
- high-mobility group box-1,
- inflammation

FullText(HTML)

References(50)

References

[1]	Deli G, Bosnyak E, Pusch G, et al. Diabetic neuropathies: diagnosis and management[J]. Neuroendocrinology, 2013, 98(4): 267–280. doi: 10.1159/000358728
[2]	Jin HY, Moon SS, Calcutt NA. Lost in translation? Measuring diabetic neuropathy in humans and animals[J]. Diabetes Metab J, 2021, 45(1): 27–42. doi: 10.4093/dmj.2020.0216
[3]	Gonçalves NP, Vægter CB, Andersen H, et al. Schwann cell interactions with axons and microvessels in diabetic neuropathy[J]. Nat Rev Neurol, 2017, 13(3): 135–147. doi: 10.1038/nrneurol.2016.201
[4]	Xi C, Zhang Y, Yan M, et al. Exogenous neuritin treatment improves survivability and functions of Schwann cells with improved outgrowth of neurons in rat diabetic neuropathy[J]. J Cell Mol Med, 2020, 24(17): 10166–10176. doi: 10.1111/jcmm.15627
[5]	Feldman EL, Nave KA, Jensen TS, et al. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain[J]. Neuron, 2017, 93(6): 1296–1313. doi: 10.1016/j.neuron.2017.02.005
[6]	Wang L, Chopp M, Szalad A, et al. Exosomes derived from Schwann cells ameliorate peripheral neuropathy in type 2 diabetic mice[J]. Diabetes, 2020, 69(4): 749–759. doi: 10.2337/db19-0432
[7]	Cinci L, Corti F, Di Cesare Mannelli L, et al. Oxidative, metabolic, and apoptotic responses of Schwann cells to high glucose levels[J]. J Biochem Mol Toxicol, 2015, 29(6): 274–279. doi: 10.1002/jbt.21695
[8]	Liu Y, Shao S, Guo H. Schwann cells apoptosis is induced by high glucose in diabetic peripheral neuropathy[J]. Life Sci, 2020, 248: 117459. doi: 10.1016/j.lfs.2020.117459
[9]	Naruse K. Schwann cells as crucial players in diabetic neuropathy[M]//Sango K, Yamauchi J, Ogata T, et al. Myelin. Singapore: Springer, 2019: 345–356.
[10]	Shi X, Chen Y, Nadeem L, et al. Beneficial effect of TNF-α inhibition on diabetic peripheral neuropathy[J]. J Neuroinflammation, 2013, 10: 836. doi: 10.1186/1742-2094-10-69
[11]	Zhou J, Zhou S. Inflammation: therapeutic targets for diabetic neuropathy[J]. Mol Neurobiol, 2014, 49(1): 536–546. doi: 10.1007/s12035-013-8537-0
[12]	Colavita L, Ciprandi G, Salpietro A, et al. HMGB1: a pleiotropic activity[J]. Pediatr Allergy Immunol, 2020, 31(Suppl 26): 63–65. doi: 10.1111/pai.13358
[13]	Andersson U, Yang H, Harris H. High-mobility group box 1 protein (HMGB1) operates as an alarmin outside as well as inside cells[J]. Semin Immunol, 2018, 38: 40–48. doi: 10.1016/j.smim.2018.02.011
[14]	Faraco G, Fossati S, Bianchi ME, et al. High mobility group box 1 protein is released by neural cells upon different stresses and worsens ischemic neurodegeneration in vitro and in vivo[J]. J Neurochem, 2007, 103(2): 590–603. doi: 10.1111/j.1471-4159.2007.04788.x
[15]	Chen Y, Qiao F, Zhao Y, et al. HMGB1 is activated in type 2 diabetes mellitus patients and in mesangial cells in response to high glucose[J]. Int J Clin Exp Pathol, 2015, 8(6): 6683–6691. https://pubmed.ncbi.nlm.nih.gov/26261550/
[16]	Robinson AP, Caldis MW, Harp CT, et al. High-mobility group box 1 protein (HMGB1) neutralization ameliorates experimental autoimmune encephalomyelitis[J]. J Autoimmun, 2013, 43: 32–43. doi: 10.1016/j.jaut.2013.02.005
[17]	Wu B, Guo Y, Chen Q, et al. MicroRNA-193a downregulates HMGB1 to alleviate diabetic neuropathic pain in a mouse model[J]. Neuroimmunomodulation, 2019, 26(5): 250–257. doi: 10.1159/000503325
[18]	Wang X, Feng C, Qiao Y, et al. Sigma 1 receptor mediated HMGB1 expression in spinal cord is involved in the development of diabetic neuropathic pain[J]. Neurosci Lett, 2018, 668: 164–168. doi: 10.1016/j.neulet.2018.02.002
[19]	Mollica L, De Marchis F, Spitaleri A, et al. Glycyrrhizin binds to high-mobility group box 1 protein and inhibits its cytokine activities[J]. Chem Biol, 2007, 14(4): 431–441. doi: 10.1016/j.chembiol.2007.03.007
[20]	Kim SW, Jin Y, Shin JH, et al. Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion[J]. Neurobiol Dis, 2012, 46(1): 147–156. doi: 10.1016/j.nbd.2011.12.056
[21]	Okuma Y, Liu K, Wake H, et al. Glycyrrhizin inhibits traumatic brain injury by reducing HMGB1–RAGE interaction[J]. Neuropharmacology, 2014, 85: 18–26. doi: 10.1016/j.neuropharm.2014.05.007
[22]	Mohammad G, Siddiquei MM, Othman A, et al. High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina[J]. Exp Eye Res, 2013, 107: 101–109. doi: 10.1016/j.exer.2012.12.009
[23]	Zhang H, Zhang R, Chen J, et al. High mobility group box1 inhibitor glycyrrhizic acid attenuates kidney injury in streptozotocin-induced diabetic rats[J]. Kidney Blood Press Res, 2017, 42(5): 894–904. doi: 10.1159/000485045
[24]	Ma J, Shi M, Zhang X, et al. GLP-1R agonists ameliorate peripheral nerve dysfunction and inflammation via p38 MAPK/NF-κB signaling pathways in streptozotocin-induced diabetic rats[J]. Int J Mol Med, 2018, 41(5): 2977–2985. doi: 10.3892/ijmm.2018.3509
[25]	Karamoysoyli E, Burnand RC, Tomlinson DR, et al. Neuritin mediates nerve growth factor–induced axonal regeneration and is deficient in experimental diabetic neuropathy[J]. Diabetes, 2008, 57(1): 181–189. doi: 10.2337/db07-0895
[26]	Tosaki T, Kamiya H, Yasuda Y, et al. Reduced NGF secretion by Schwann cells under the high glucose condition decreases neurite outgrowth of DRG neurons[J]. Exp Neurol, 2008, 213(2): 381–387. doi: 10.1016/j.expneurol.2008.06.017
[27]	Li J, Zhang H, Xie M, et al. NSE, a potential biomarker, is closely connected to diabetic peripheral neuropathy[J]. Diabetes Care, 2013, 36(11): 3405–3410. doi: 10.2337/dc13-0590
[28]	Dincel GC, Yildirim S. Overexpression of ADAMTS-13 and neuronal nitric oxide synthase relates with neuropathology in streptozotocin-induced type 1 diabetic rats[J]. Int J Clin Exp Pathol, 2016, 9(4): 4761–4778. https://www.researchgate.net/publication/304379452
[29]	Cheng Y, Liu J, Luan Y, et al. Sarm1 gene deficiency attenuates diabetic peripheral neuropathy in mice[J]. Diabetes, 2019, 68(11): 2120–2130. doi: 10.2337/db18-1233
[30]	Min S, Li J, Zhang H, et al. Neuritin is expressed in Schwann cells and down-regulated in apoptotic Schwann cells under hyperglycemia[J]. Nutr Neurosci, 2012, 15(6): 264–270. doi: 10.1179/1476830512Y.0000000022
[31]	Ugrinova I, Pasheva E. HMGB1 protein: a therapeutic target inside and outside the cell[J]. Adv Protein Chem Struct Biol, 2017, 107: 37–76. doi: 10.1016/bs.apcsb.2016.10.001
[32]	Andersson U, Yang H, Harris H. Extracellular HMGB1 as a therapeutic target in inflammatory diseases[J]. Expert Opin Ther Targets, 2018, 22(3): 263–277. doi: 10.1080/14728222.2018.1439924
[33]	Salo H, Qu H, Mitsiou D, et al. Disulfide and fully reduced HMGB1 induce different macrophage polarization and migration patterns[J]. Biomolecules, 2021, 11(6): 800. doi: 10.3390/biom11060800
[34]	Gao T, Chen Z, Chen H, et al. Inhibition of HMGB1 mediates neuroprotection of traumatic brain injury by modulating the microglia/macrophage polarization[J]. Biochem Biophys Res Commun, 2018, 497(1): 430–436. doi: 10.1016/j.bbrc.2018.02.102
[35]	Kigerl KA, Lai W, Wallace LM, et al. High mobility group box-1 (HMGB1) is increased in injured mouse spinal cord and can elicit neurotoxic inflammation[J]. Brain Behav Immun, 2018, 72: 22–33. doi: 10.1016/j.bbi.2017.11.018
[36]	Venereau E, De Leo F, Mezzapelle R, et al. HMGB1 as biomarker and drug target[J]. Pharmacol Res, 2016, 111: 534–544. doi: 10.1016/j.phrs.2016.06.031
[37]	Yan S, Fang C, Cao L, et al. Protective effect of glycyrrhizic acid on cerebral ischemia/reperfusion injury via inhibiting HMGB1-mediated TLR4/NF-κB pathway[J]. Biotechnol Appl Biochem, 2019, 66(6): 1024–1030. doi: 10.1002/bab.1825
[38]	Kamiya H, Zhangm W, Sima AAF. Apoptotic stress is counterbalanced by survival elements preventing programmed cell death of dorsal root ganglions in subacute type 1 diabetic BB/Wor rats[J]. Diabetes, 2005, 54(11): 3288–3295. doi: 10.2337/diabetes.54.11.3288
[39]	Mnich K, Carleton LA, Kavanagh ET, et al. Nerve growth factor-mediated inhibition of apoptosis post-caspase activation is due to removal of active caspase-3 in a lysosome-dependent manner[J]. Cell Death Dis, 2014, 5(5): e1202. doi: 10.1038/cddis.2014.173
[40]	Guo X, Shi Y, Du P, et al. HMGB1/TLR4 promotes apoptosis and reduces autophagy of hippocampal neurons in diabetes combined with OSA[J]. Life Sci, 2019, 239: 117020. doi: 10.1016/j.lfs.2019.117020
[41]	Ma Y, Du Y, Xu Q, et al. Inhibiting MiR-34α reduces retinal cell apoptosis and downstream NF-κB pathway in diabetic retinopathy rats through regulating HMGB1 expression[J]. Minerva Med, 2020. doi: 10.23736/S0026-4806.20.06625-2. [Epub ahead of print
[42]	Hudson BI, Lippman ME. Targeting RAGE signaling in inflammatory disease[J]. Annu Rev Med, 2018, 69: 349–364. doi: 10.1146/annurev-med-041316-085215
[43]	Paudel YN, Angelopoulou E, Piperi C, et al. Impact of HMGB1, RAGE, and TLR4 in Alzheimer's disease (AD): from risk factors to therapeutic targeting[J]. Cells, 2020, 9(2): 383. doi: 10.3390/cells9020383
[44]	Purves T, Middlemas A, Agthong S, et al. A role for mitogen-activated protein kinases in the etiology of diabetic neuropathy[J]. Faseb J, 2001, 15(13): 2508–2514. doi: 10.1096/fj.01-0253hyp
[45]	Yang DP, Kim J, Syed N, et al. p38 MAPK activation promotes denervated Schwann cell phenotype and functions as a negative regulator of Schwann cell differentiation and myelination[J]. J Neurosci, 2012, 32(21): 7158–7168. doi: 10.1523/JNEUROSCI.5812-11.2012
[46]	Stavniichuk R, Obrosov AA, Drel VR, et al. 12/15-Lipoxygenase inhibition counteracts MAPK phosphorylation in mouse and cell culture models of diabetic peripheral neuropathy[J]. J Diabetes Mellitus, 2013, 3(3): 101–110. doi: 10.4236/jdm.2013.33015
[47]	Li L, Ling Y, Huang M, et al. Heparin inhibits the inflammatory response induced by LPS and HMGB1 by blocking the binding of HMGB1 to the surface of macrophages[J]. Cytokine, 2015, 72(1): 36–42. doi: 10.1016/j.cyto.2014.12.010
[48]	Tan J, Zhao F, Deng S, et al. Glycyrrhizin affects monocyte migration and apoptosis by blocking HMGB1 signaling[J]. Mol Med Rep, 2018, 17(4): 5970–5975. doi: 10.3892/mmr.2018.8598
[49]	Xie W, Zhu T, Dong X, et al. HMGB1-triggered inflammation inhibition of notoginseng leaf triterpenes against cerebral ischemia and reperfusion injury via MAPK and NF-κB signaling pathways[J]. Biomolecules, 2019, 9(10): 512. doi: 10.3390/biom9100512
[50]	Chu Y, Wang Y, Zheng Z, et al. Proinflammatory effect of high glucose concentrations on HMrSV5 cells via the autocrine effect of HMGB1[J]. Front Physiol, 2017, 8: 762. doi: 10.3389/fphys.2017.00762